Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 02, 2008. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the issued share capital as of August 31, 2008:
- Total issued Ordinary shares: 5,711,555,188 (25p each).
- Treasury shares held: 474,194,158.
- Total voting rights: 5,237,361,030.
No material changes to financial performance or operational status are reported in this text.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. The primary purpose is to provide the denominator for shareholders to calculate notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,237,361,030) against the latest share register.
- Confirm the number of shares held in Treasury (474,194,158) to ensure accurate calculation of beneficial ownership thresholds.
- Check subsequent filings for financial performance data, as this 6-K does not contain earnings or cash flow information.